Last update 25 May 2025

SurVaxM

Overview

Basic Info

Drug Type
Synthetic peptide vaccine, Therapeutic vaccine
Synonyms
SurVaxM, Survivin peptide mimic vaccine, Survivin-targeted peptide vaccine
+ [1]
Target
Action
inhibitors
Mechanism
survivin inhibitors(Baculoviral IAP repeat-containing protein 5 inhibitors)
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastro-Enteropancreatic Neuroendocrine TumorPhase 2
United States
15 Jun 2025
Malignant Solid NeoplasmPhase 2
United States
15 Jun 2025
Neuroendocrine neoplasm of lungPhase 2
United States
15 Jun 2025
Neuroendocrine tumor of pancreasPhase 2
United States
15 Jun 2025
GlioblastomaPhase 2
China
21 Sep 2022
Glioblastoma MultiformePhase 2
United States
04 May 2015
GliosarcomaPhase 2
United States
04 May 2015
Carcinoid TumorPhase 1
United States
17 Jun 2019
Pancreatic neuroendocrine tumour metastaticPhase 1
United States
17 Jun 2019
Plasma Cell LeukemiaPhase 1
United States
13 Apr 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Glioblastoma
First line
-
SurVaxM + SOC
ijojzjzeyl(jyjdnrvhvh) = has successfully progressed following the first interim analysis of trial data. rldunxdcbb (rlbosscxhl )
Positive
12 Feb 2025
Phase 2
Glioblastoma
Adjuvant
66
SurVaxM plus adjuvant TMZ
kwibqphnss(qobjolrykj) = qqmejgeiea rkrlotvyke (awvtqolfse )
Positive
15 Dec 2022
Phase 2
63
knxafbgysa(mqmcpkfnzi) = jbopvrdwor qrswhbktty (ellidlimzx )
Positive
02 Jun 2022
Phase 2
66
hvqqbqqpmh = dbnesshzzq kmtgyzunos (abwbsiglar, ngbazuzfag - nmgoluvqzo)
-
01 Feb 2021
Phase 2
Glioblastoma
First line
survivin positive
63
standard therapy+SurVaxM
(methylated MGMT)
zhfvagruov(zucbjkvwzt) = injection site reactions zezehaaryy (gtpeoacyoz )
Positive
26 May 2019
standard therapy+SurVaxM
(unmethylated MGMT)
Phase 2
Glioblastoma
Adjuvant | Maintenance
HLA-A*02 | MGMT methylated
-
fdmbbccecx(tgmfhnhhia) = voafyywsfh kwlhrciqwy (turrrtslow, 83.0% - 98.1)
Positive
05 Nov 2018
Phase 2
63
dkqftjhfsd(bntnewdjkl) = immunization-related adverse events were mild with no serious adverse events attributable to SurVaxM lwloqlayxz (eknlslikvj )
Positive
01 Jun 2018
Phase 1
Recurrent Malignant Glioma
HLA-A*02 | HLA-A*03
9
ctewsfsbpo(jxrqgmyrky) = 3 patients reported grades 1 or 2 fatigue jlyerrcagn (afzdusrtwn )
Positive
01 Nov 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free